Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)

Market Cap	9.28B -31.1%
Revenue (ttm)	2.75B -8.3%
Net Income	279.32M -40.3%
EPS	1.20 -40.0%
Shares Out	226.13M
PE Ratio	19.05
Forward PE	n/a
Dividend	1.13 (4.99%)
Ex-Dividend Date	n/a

Volume	105,420
Average Volume	176,772
Open	22.60
Previous Close	22.70
Day's Range	22.22 - 23.38
52-Week Range	21.70 - 31.28
Beta	0.52
RSI	36.83
Earnings Date	Mar 20, 2026

About HKG:6826

Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in China, Europe, the United States, and internationally. It offers ophthalmology products consist of intraocular lens, medical sodium hyaluronate gel, and lubricant eye drop. The company also offers sodium hyaluronate injection, medical chitosan, medical sodium hyaluronate gel, anti-adhesion, and burn wound related products. In addition, it provides injectors, scalpels, suture needles and other products. Further, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 2,156
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6826

Financial Performance

In 2025, HKG:6826's revenue was 2.47 billion, a decrease of -7.71% compared to the previous year's 2.68 billion. Earnings were 251.01 million, a decrease of -40.30%.

Financial numbers in CNY